Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Advaxis Inc (NASDAQ:ADXS)

7.91
Delayed Data
As of Jun 24
 -0.26 / -3.18%
Today’s Change
5.21
Today|||52-Week Range
22.20
-21.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$287.8M

Company Description

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company's platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Information

Advaxis, Inc.
305 College Road East
Princeton New Jersey 08540
P:(609) 452-9813
Investor Relations:

Employees

Shareholders

Other institutional36.56%
Mutual fund holders25.98%
Individual stakeholders22.89%

Top Executives

Daniel J. O'ConnorPresident, Chief Executive Officer & Director
Gregory T. MayesCOO, Secretary, Director & Head-Investor Relations
Sara BonsteinChief Financial Officer & Senior Vice President
Robert G. PetitChief Scientific Officer & Executive VP
Mayo PujolsVice President-Manufacturing